Company: IPSC
Filing Date: 2025-07-10
Form Type: S-3
Source: 0001104659-25-067022
Chunk: 42

Company: Century Therapeutics, Inc.
Filing Date: 2025-07-10
Form: S-3
Chunk 42
---
 under this prospectus without delivery, in paper format or in electronic format, or both, of the applicable prospectus supplement describing the method and terms of the offering.

Under Rule 15c6-1 of the Exchange Act, trades in the secondary market generally are required to settle in one business day, unless the parties to any such trade expressly agree otherwise. The applicable prospectus supplement may provide that the original issue date for your securities may be more than one scheduled business day after the trade date for your securities. Accordingly, in such a case, if you

<div align='center'>30</div>

TABLE OF CONTENTS

wish to trade securities on any date prior to the first business day before the original issue date for your securities, you will be required, by virtue of the fact that your securities initially are expected to settle in more than one scheduled business day after the trade date for your securities, to make alternative settlement arrangements to prevent a failed settlement.

The securities may be new issues of securities and may have no established trading market. The securities may or may not be listed on a national securities exchange. We can make no assurance as to the liquidity of or the existence of trading markets for any of the securities.

<div align='center'>31</div>

TABLE OF CONTENTS

### LEGAL MATTERS
Goodwin Procter LLP, Philadelphia, PA, will pass upon certain legal matters relating to the issuance and sale of the securities offered hereby on behalf of Century Therapeutics, Inc. Additional legal matters may be passed upon for us or any underwriters, dealers or agents by counsel that we will name in the applicable prospectus supplement.

<div align='center'>32</div>

TABLE OF CONTENTS

### EXPERTS
The consolidated financial statements of Century Therapeutics, Inc. appearing in Century Therapeutics, Inc’s Annual Report (Form 10-K) for the year ended December 31, 2024, have been audited by Ernst & Young LLP, independent registered public accounting firm, as set forth in their report thereon included therein, and incorporated herein by reference. Such financial statements are, and audited financial statements to be included in subsequently filed documents will be, incorporated by reference herein in reliance upon the reports of Ernst & Young LLP pertaining to such financial statements (to the extent covered by consents filed with the Securities and Exchange Commission) given on the authority of such firm as experts in accounting and auditing.

<div align='center'>33</div>

TABLE OF CONTENTS

PART II INFORMATION NOT REQUIRED IN PRO